2024

2023

DECMOU signed with BioSolvix Co., Ltd.
SF-Rx Patent Application (US)
CombiNet Patent Application (PCT)
NDC-011 (ALS) U.S. FDA Pre-IND Meeting
NOVSelection of Daewoong Pharmaceutical Co., Ltd. for the NeuroRG competition and joint R&D
NOVNDC-060 (Dementia) Patent Application (Argentina, Taiwan)
CombiNet Patent Registration (Korea, two patents)
SEPPublished in Neurotherapeutics
"Therapeutic Effects of Combination of Nebivolol and Donepezil: Targeting Multifactorial Mechanisms in ALS"
SEPNDC-060 (Dementia) Patent Registration (Korea)
CombiNet Patent Registration (Korea)
NDC-060 (Dementia) Patent Application (PCT)
NDC-002 (Stroke Recovery) U.S. FDA Pre-IND Meeting
NDC-011 (ALS) U.S. FDA approved for ODD
AUGNDC-011 (ALS) Patent Application (USA, Europe, Argentina)
JULNDC-002 (Stroke Recovery) Phase 1 clinical trials CSR completed
JUNNDC-002 (Stroke Recovery) Patent Application (Europe, Canada, Brazil, Australia, India, China, Japan)
NDC-002 (Stroke Recovery) / NDC-060 (Dementia) Integrated Patent Application in the United States
NDC-011 (ALS) Signed FDC Development and Production Agreement with Global CDMO (Producer: United States)
MARNDC-002 (Stroke Recovery) Phase 1 clinical trials completed and Report termination to MFDS
CombiNet Patent Application (Korea, two patents)
FEBNDC-011 (ALS) Patent Application (PCT)
CombiNet Patent Application (Korea)
JANNDC-002 (Stroke Recovery) Drug administration for Phase 1 clinical trials in Korea

DECNDC-002 (Stroke Recovery) Recruitment of Phase 1 clinical trials
DECNDC-002 (Stroke Recovery) Patent Application (PCT)
NDC-060 (Dementia) Patent Application (Korea)
Signed consignment research contract with Vasthera Co., Ltd.
AUGNeuroRG Patent Registration (Korea)
JULNeuroRG PCT Application
MAYSeries B Investment completed (Gradiant, CKD, L&S, Yuantainvestment, and more)
APRNDC-002 (Stroke Recovery) Approved IND for Phase 1 Clinical Trial by MFDS (Korea)
FEBLaunching AI platform technology business (NeuroRG)
JANPatent application for candidate materials for SK Chemicals joint R&D (3 cases)